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The biological activity of nanoparticle-directed therapies critically depends on cellular targeting. 
We examined the subtumoral fate of Particle Replication in Non-Wetting Templates (PRINT) 
nanoparticles in a xenografted melanoma tumor model by multi-color flow cytometry and in vivo 
confocal tumor imaging. These approaches were compared with the typical method of whole-
organ quantification by radiolabeling. In contrast to radioactivity based detection which 
demonstrated a linear dose-dependent accumulation in the organ, flow cytometry revealed that 
particle association with cancer cells became dose-independent with increased particle doses and 
that the majority of the nanoparticles in the tumor were associated with cancer cells despite a low 
fractional association. In vivo imaging demonstrated an inverse relationship between tumor cell 
association and other immune cells, likely macrophages. Finally, variation in particle size 
nonuniformly affected subtumoral association. This study demonstrates the importance of 
subtumoral targeting when assessing nanoparticle activity within tumors.
Graphical abstract
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Background
Appreciation of the Enhanced Permeation and Retention (EPR) effect for nanocarrier-
mediated drug delivery in oncology has resulted in a focus on the accumulation of particles 
in whole tumors.1 A range of methods to determine the fraction of the injected dose of the 
carrier or cargo that accumulates in a whole organ or tumor has driven the assessment of 
nanoparticle targeting to solid tumors.2–13 However, tumors are composed of a variety of 
cell types, such as fibroblasts and endothelial cells and macrophages and neutrophils, in 
addition to cancer cells. The relative distribution of these cell types varies between 
tumors.14–17 Whole organ approaches are unable to discriminate between accumulation in 
the intended target, typically cancer cells, and other cells or the extracellular space. For 
cargo with an intracellular mechanism of action, such as nucleic acids and proteins, delivery 
to specific cell types is crucial to assessing nanoparticle efficacy and optimizing targeting.
Methods for the identification of subtumoral cellular components include microscopy and 
flow cytometry. Confocal microscopy has been used to determine particle internalization in 
vivo by analyzing multiple sections of an organ.18 However, meaningful quantification can 
be challenging. Flow cytometry permits concurrent cellular identification and nanoparticle 
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quantification. Previous studies that have used flow cytometry to examine nanoparticle 
targeting to organs have not explored the effects of particle characteristics (composition, 
shape, etc.) or dose on the accumulation in specific cell populations and do not correlate 
their findings with whole organ assessment.14,19–25 Studies that account for both nanocarrier 
properties as well as intra-organ or intra-tumor distribution have the potential to best inform 
nanoparticle design and delivery.
PRINT is a top-down fabrication strategy that relies on precision molds, offering the 
advantage of reproducible production of monodisperse particles. This reproducibility 
eliminates large variation in particle sizes (i.e. PDI) that could influence the association of a 
subset of the particles with one cell population over another confounding data interpretation. 
In addition, PRINT also affords homogeneity in the composition of the particles and 
flexibility in the composition of the desired nanoparticle material.
Using flow cytometry, whole organ assessment and live animal in vivo confocal microscopy, 
we analyzed the cell type-specific distribution of PRINT nanoparticles. We identified wide 
variation in subtumoral cellular association and identify dose and particle properties that 
influence cellular targeting.
Methods
Materials
Poly(ethylene glycol) diacrylate (Mw 700) (PEG700DA), 2-aminoethyl methacrylate 
hydrochloride (AEM), diphenyl (2,4,6-trimethylbenzoyl)-phosphine oxide (TPO), and 
sucrose were purchased from Sigma-Aldrich. Thermo Scientific Dylight 488 maleimide, 
dimethylformamide (DMF), triethylamine (TEA), pyridine, borate buffer (pH 8.6), acetic 
anhydride, and methanol were obtained from Fisher Scientific. Conventional filters (2 µm) 
were purchased from Agilent and poly(vinyl alcohol) (Mw 2000) (PVOH) was purchased 
from Acros Organics. PRINT molds (80 nm×80 nm×320 nm) were obtained from Liquidia 
Technologies. Tetraethylene glycolmonoacrylate (HP4A) was synthesized in-house as 
previously described.26 Methoxy-PEG(5k)-succinimidyl carboxy methyl ester (mPEG5k-
SCM) was purchased from Creative PEGWorks. Typsin, DPBS, and cell culture media were 
purchased from Gibco.
PRINT nanoparticle fabrication and characterization
The PRINT particle fabrication technique has been described previously in detail.27,28 The 
pre-particle solution was prepared by dissolving 3.5 wt% of the various reactive monomers 
in methanol. The preparticle solution was comprised of 67.75 wt% HP4A, 20 wt% AEM, 10 
wt% PEG700DA, 1 wt% TPO and 1.25 wt% Dylight 488 maleimide. Stock particle 
concentrations were determined by thermogravimetric analysis (TGA) on both an aliquot of 
the stock and a centrifuged sample of the stock, to account for any mass due to PVOH, using 
a TA Instruments Q5000. Particles were visualized by scanning electron microscopy (SEM) 
using a Hitachi S-4700 SEM. Prior to imaging, SEM samples were coated with 3.5 nm of 
gold-palladium alloy using a Cressington 108 auto sputter coater. Particle size and zeta 
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potential were measured by dynamic light scattering (DLS) on a Zetasizer Nano ZS 
(Malvern Instruments, Ltd.).
Particles were PEGylated and acetylated following a previously described method.27 Post-
acetylation, particles were analyzed by TGA, DLS and SEM and stored at 4°C. To radiolabel 
the nanoparticles, high specific activity 64Cu (14000±7600 Ci/mmol or 518±28 TBq/mmol) 
was obtained from the Washington University School of Medicine (St. Louis, MO, 
USA). 64Cu was produced on a CS-15 biomedical cyclotron by the 64Ni(p,n)64Cu nuclear 
reaction using previously established methods29, with a half-life of 12.7 hours. Following 
PEGylation (described above), particles were characterized as described above by TGA and 
reacted in 0.1 M Na2CO3 buffer (pH 9) with 2-(4-isothiocyanatobenzyl) 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (p-SCN-Bn-DOTA) at 5 mg/mL (2:1 
DOTA:AEM molar ratio). A conversion from positive to negative zeta potential indicated 
that the reaction went to completion. Particles were then incubated with 64CuCl2 for 30 
minutes at 65 °C in 0.1 M ammonium acetate, washed 3 times by centrifugation with 
deionized water, and resuspended for injection in 9.25% sucrose.
Cells, cell culture, and spheroid injections
Cells were cultured as previously described in high glucose DMEM (Gibco) with 10% FBS 
(Gemini Bio-products) and 1% Penicillin/Streptomycin (Gibco).30 Hanging droplet 
spheroids were generated by trypsinization of the cells and resuspension to 2 × 106 cells/mL. 
Twenty microliters of the cell suspension was pipetted into wells of a 60-well minitray 
(Nunc, Thermofisher scientific). The minitray was inverted and placed in a humidified 150 
mm dish. Cells were incubated at 37 °C and 5% CO2 for 4–6 days. Individual spheroids 
were harvested and verified visually. Athymic nude mice were anesthetized by inhalation 
with 2% isoflurane. A mouse ear was affixed onto a conical tube with double-sided tape. 
The tumor spheroid were injected as described30. Successful spheroid injection was verified 
by epifluorescence macroscopic imaging (Supplemental Figure S1A).
Mice and Particle Injections
All animals were handled according to the NIH Guide for the Care and Use of Laboratory 
Animals. All Procedures were approved by the University of North Carolina-Chapel Hill 
Institutional Animal Care and Use Committee (IACUC), protocol #11–154.0. 4–8 week old, 
male Foxn1nu (athymic; C57BL/6J background) nude mice were purchased from the UNC 
Animal Services Core. Nanoparticles were suspended in isotonic 9.25% sucrose and injected 
intravenously via the tail vein at a maximum of 300 µl per animal. Tumors were of equal 
volumes between groups and ranged from 100–300mm3, as determined using caliper 
measurements using the formula V=(L/2)×(W/2)×(H/2)×(4/3×π) (Supplemental Figure 
S1A). Particles were resuspended at different concentrations (1.45, 4.65, 14.65 mg/mL) to 
deliver similar injection volumes of approximately 300 µl.
Tumor Dissociation and Flow Cytometry
Tumors were harvested as described with slight modifications.31 Briefly, tumors were 
dissociated for 3 hours in 5 mL of DMEM with 10% FBS containing 1500 U collagenase 
and 500 U hyaluronidase (10× collagenase/hyaluronidase, StemCell Technologies). After 
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centrifugation (600 ×g for 5 minutes), cell pellets were resuspended in a 1:4 mixture of 
HEPES Buffered Saline containing 2% FBS (HF solution) and RBC Lysis Buffer (0.8% 
NH4Cl and 0.1 mM EDTA, Stem Cell Technologies), recentrifuged (450 × g for 5 minutes) 
then resuspended in RBC lysis buffer. After centrifugation, cells were resuspended in 0.05% 
Trypsin/EDTA solution (Gibco) and incubated 5 minutes at 37 °C. Cells were pelleted and 
resuspended in Dispase (1 U/mL) and DNase I (0.1 mg/mL). After 30 minute incubation at 
37 °C, 10 mL of HF solution was added, and cells were passed through a 40 µm cell strainer 
(Fisher), centrifuged and resuspended in HF solution. Cells were then washed and counted 
with a hemocytometer. Live-Dead Fixable Blue (Invitrogen) was then added at a 
concentration of 1 µl/4×106 cells in 1 mL PBS and incubated on ice for 15 minutes. Cells 
were washed with PBS and then resuspended in 100 µl PBS. Fc Block (BD Biosciences) was 
incubated with the sample for 5 minutes on ice followed by an antibody (Biolegend) mixture 
consisting of PE-Cy7 CD31 (clone 390), APC F4/80 (clone BM8), Alexa 700 Ly6G (clone 
1A8), and Pacific Blue CD45 (clone 30-F11). After 1 hour on ice, cells were washed with 
PBS and fixed in 500µl of 4% paraformaldehyde for 15 minutes at room temperature. Cells 
were washed twice with FACS buffer (1% FBS in PBS), then resuspended in a final volume 
of 500 µl of FACS Buffer and stored at 4°C until data acquisition (LSRII, BD Biosciences). 
Data analysis of FCS3 files was performed using FACSDiva version 10.6 (BD Biosciences). 
Live Dead Blue (Invitrogen) was used to gate on the living cells. All surface markers were 
compared to their fluorescence minus one (FMO) controls to set appropriate gates. Particle 
association was determined by comparison to control sucrose injected animals to establish 
appropriate gating.
Two-photon Microscopy
Tumor-bearing animals with tumors between 10–30mm3 were imaged as previously 
described.30 Animals were anesthetized with isofluorane, and tumors were imaged before 
and after administration of particles. All imaging was performed at 910 nm with an Olympus 
FV1000MPE mounted on an upright BX-61WI microscope, using a 25×, 1.05 N.A. (2 mm 
W.D.) water immersion objective with optical imaging gel to capture images. Olympus 
Fluoview software and microscope settings were consistent for all acquired images (the laser 
power was at 14% and each channel’s PMT voltage was 580, 635, and 600, respectively). 
The laser unit (MaiTai DeepSee) is tunable from 690–1040 nm with a pulse width < 100 fs. 
Three channel non-descan detectors were used: Ch1 (420–460 nm) BFP, Ch2 (495–540nm) 
GFP, Ch3 (575–630 nm) RFP.
Statistics
All data, unless otherwise noted, were analyzed using a one-way ANOVA and Tukey’s post-
hoc analysis. Mean fluorescence data was analyzed using a two-way ANOVA and Tukey’s 
post-hoc analysis.
Results
PRINT fabrication
To explore the influence of particle characteristics on nanoparticle association, we generated 
tumor spheroids from LKB498 mouse melanoma cells that stably express the red fluorescent 
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protein tdTomato.30 Tumor cell spheroids were implanted intradermally and allowed to grow 
to a size of ~100 mm3 (Supplemental Figure S1A–B). Nanoparticles were fabricated using 
the Particle Replication in Non- Wetting Templates (PRINT) technique.27,28,32 PRINT 
generates nanoparticles of highly consistent and precise size, shape, and composition, 
eliminating variables which could influence cellular targeting. 80 nm×80 nm×320 nm 
PRINT nanoparticles were composed of a covalently cross-linked hydrogel matrix and were 
PEGylated as previously described.27 Depending on the assay, fluorescent moieties were 
incorporated, or copper-64 (64Cu) was chelated to the particles. Particles were characterized 
by DLS and SEM and demonstrated a similar negative zeta potential and narrow size 
distribution (Supplemental Figure S1C).
To determine nanoparticle accumulation using a whole-organ based approach, 64Cu 
radiolabeled PRINT nanoparticles were administered IV at several doses into tumor bearing 
mice. Eighteen hours following particle administration, animals were sacrificed and organs 
were harvested. Gamma emission was measured from several organs and the tumor 
accounting for ~70% of the injected dose. Radioactive signal demonstrated a wide 
distribution, ranging from ~45% of particles associated with the liver to ~0.2% of particles 
associated with the heart (Figure 1A). This particle distribution is consistent with other types 
of nanoparticles2,12,13,18. The relative fraction of the injected dose detected in each organ 
was unaffected by dose (Figure 1A). However, the total amount of particles contained within 
the tumor as well as in each organ increased in a dose-dependent manner (Figure 1B and 
Supplemental Figure S2).
Sub-organ Particle Accumulation
We then examined the cellular composition of our tumor model. Tumors were enzymatically 
dissociated to create a single cell suspension and analyzed using multi-color flow cytometry 
(Figure 2). After gating on viable cells, tdTomato fluorescence identified the melanoma 
cells. To distinguish these cells from the other cell compartments that comprise the entirety 
of the tumor, we refer to these cells as “cancer cells” hereafter. The remaining non-cancer 
cells were separated into an immune cell population based on CD45 expression (leukocyte 
marker). CD45+ cells were further subdivided by the expression of F4/80, which marks 
mouse macrophages, or Ly6G, which marks neutrophils. CD45+ F4/80− Ly6G− cells were 
classified as “other leukocytes” representing a mixture of cells that includes natural killer 
cells, dendritic cells, and B cells. CD31 surface expression in the CD45− cell population 
identified endothelial cells, with the remaining CD45− and CD31− populations classified as 
fibroblast/other. Surface markers were compared to their fluorescence minus one (FMO) 
controls to ensure appropriate population gating. The tumor cell suspension reproducibly 
contained 89.9% cancer cells, 3.2% neutrophils, 1.1% macrophages, 0.64% other 
leukocytes, 0.49% endothelial cells, and 3.3% fibroblast/other cells (Figure 3). This gating 
strategy accounted for virtually all cells (98.6%) isolated from the tumor.
Mice were injected with fluorescent 80 × 80 × 320 nanoparticles at several doses or with a 
sucrose control. 18 hours after treatment, tumors were dissected from mice, dissociated, and 
analyzed by flow cytometry as described. Cancer cells demonstrated a dose-dependent 
association at doses between 12.5 to 40 mg/kg, yielding 1.5% or 5.2% particle positive cells, 
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respectively (Figure 4A). At the 125 mg/kg dose, 6.2% association was observed. These data 
indicate a dose dependent increase in fractional association with an upper limit that becomes 
independent of dose. In vitro association data also revealed a lack of particle association at 
high doses (Supplemental Figure S3). Since tdTomato fluorescence could obscure or 
artifactually contribute to particle signal, the fractionation experiment was repeated using 
non-fluorescent cancer cells. These data demonstrated that the relationship between 
fluorescence-based quantitation of particle association and dose was unaffected by the 
presence of tdTomato or by compensation-associated corrections, both in vitro and in vivo, 
although there was a slight shift in the gated population (Supplemental Figure S3 and S4).
Non-cancer cell populations showed a greater fractional particle association. Approximately 
15–35% of endothelial cells were positive for particle association (Figure 4A), whereas 
fibroblast/other cells exhibited the lowest fractional association of 5–20% (Figure 4C). 20–
60% of neutrophils, 60–80% of macrophages, and 20–60% other leukocytes were associated 
with PRINT particles (Figure 4D–F). Strikingly, in contrast to macrophages and cells in the 
other leukocyte classes which demonstrated a sustained dose-dependent increase in 
nanoparticle association, cancer cells, endothelial cells, and cells in the fibroblast/other 
class, showed no increase in fractional association above the 40 mg/kg dose. These data 
suggest a limit to nanoparticle uptake, possibly based on the number of cells sufficiently 
proximal to blood vessels to contact particles or the capacity of these cells to take up the 
particles.
We then quantified fluorescence for individual cells. Among the cells analyzed, 
macrophages demonstrate the greatest mean fluorescence intensity (MFI) (Figure 5). MFI 
for macrophages was approximately 3.5 fold greater than that of the cancer cells, indicating 
that macrophages associate with a greater number of particles per cell. Similar to fractional 
association, fluorescence signal per cell increased in a dose-dependent fashion at the low 
doses for cancer cells as well as immune cells. However, signal in cancer cells plateaued 
despite increased dose. These data suggest that a subset of cells are able to associate with 
particles and, further, that these cells have a biological limitation on their ability to take up 
particles. Using the mean fluorescence data, the relative fluorescence in each cell 
compartment was calculated. These data demonstrated that although a low fraction of cancer 
cells are particle-positive, after adjusting for the fraction of cancer cells within the sample, 
cancer cells represent the cell type with the largest relative accumulation of particles 
(Supplemental Figure S5).
We then explored the fate of nanoparticles in the tumors of live mice by intravital two-
photon microscopy. Mice harboring tdTomato+ LKB498 tumors were anesthetized and 
imaged before and after intravenous injection of 40mg/kg Dylight488 conjugated 
nanoparticles. The use of an excitatory wavelength of 910nm enabled simultaneous imaging 
of the tumor (tdTomato), the fluorescent nanoparticles (Dylight488), and bundled collagen 
(via second harmonic generation signal, SHG). As early as 10 minutes after nanoparticle 
injection, we observed the presence of nanoparticles within the tumor, which was 
demonstrated by the colocalization of red and green fluorescence suggesting the presence of 
particles associated with tumor cells (Figure 6A, Supplemental Figure S6). We also 
observed, however, a cell population with greater fluorescence intensity. Based on flow 
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cytometry, we suspect that these bright cells are immune cells such as macrophages. We 
examined this pattern over several days holding imaging settings constant. In regions 
exhibiting few of these bright cells, colocalization between tdTomato+ tumor cells and 
Dylight488 nanoparticles was increased compared to regions of high cell infiltration (Figure 
6B). This inverse relationship suggests regional variation within the tumor such that cancer 
cell particle association is more robust in macrophage-free areas of the tumor We also 
performed two-photon microscopy on normal ear dermis to explore particle accumulation in 
normal dermal tissue. We observed that particle fluorescence remains detectable only in 
apparent vascular spaces (Supplemental Figure S7). These data may indicate the role of 
tumor vasculature and EPR in PRINT nanoparticle delivery to the cells that make up the 
tumor.
Effect of Particle Size on Association
We then asked whether altering particle properties would selectively influence subtumoral 
cellular association. Focusing on size, 55 × 70 nm particles were fabricated and 
functionalized as before (Supplemental Figure 8). Compared with the 80 × 320 nm particles, 
the 55 × 70 nm particles demonstrated a significant increase in cancer cell (4.5 % vs 2.5%) 
and macrophage association (65% vs 37%) (Figure 7A,E). However, this effect was not 
universal. Fractional associations for neutrophils, other leukocytes, endothelial cells, and 
fibroblast/other cells were not affected (Figure 7B–D,F). The mean fluorescence intensity of 
the particle-positive cells was similar across particle sizes (Figure 8), indicating that the cells 
associate with a similar particle mass. Relative distribution of the cells as calculated from 
fluorescence suggests that smaller particle size increases relative cancer cell association 
(Supplemental Figure S9). These data indicate that varying particle size can shift subtumoral 
targeting enhancing cancer cell deposition.
Discussion
The accurate quantification of nanoparticle association with tumors poses many challenges. 
Commonly, tumors are regarded as a homogeneous mass without attention to the range of 
cellular components and regional variation.14–17 To understand subtumoral distribution of 
nanoparticles, we took advantage of highly uniform PRINT nanoparticles to examine the 
single-cell fate of particles in an orthotopic spheroid tumor model. We observed a striking 
discordance between whole-tumor and individual cell analysis. Whole-organ quantification 
demonstrated dose-dependent accumulation. In contrast, cell-specific analysis revealed that 
delivery becomes dose-independent at higher doses for cancer cell population. We observed 
that macrophages associate with more particles per cell as compared to cancer cells. 
Although the relationship between tumor cell and macrophage number will vary between 
tumors, in this model cancer cells associated with the greatest number and mass of 
nanoparticles. Since flow cytometry is unable to discriminate between internalized and 
surface bound particles, intravital two-photon imaging was used to examine the fate of 
nanoparticles in an intact animal. These data, supported flow cytometry results, suggest that 
local immune cells disproportionately accumulate nanoparticles and may regionally 
influence cancer cell uptake. Flow cytometry also demonstrated the non-uniform influence 
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of particle properties on subtumoral particle distribution. Reduced particle size increased the 
association with cancer cells.
Nanomedicines can be used to passively accumulate small molecule cargo (e.g. 
chemotherapy) in tumors via the EPR effect. However, biologically active, membrane-
impermeable cargo (e.g. siRNA) requires intracellular and cell-specific delivery. Single-cell 
assessment offers lineage-specific quantification of nanoparticle targeting. The discrepancy 
between whole organ and single cell assessment limits the way radioactivity-based 
accumulation experiments can be interpreted. It is possible that at higher doses, particles 
accumulate predominantly in the extracellular space as interactions due to charge33,34 or 
particle size5,35 affect the volume available for nanoparticle diffusion36,37. Given these 
physical constraints and limited capacity for cellular association with particles, excess 
particles may accumulate in the extracellular space or be taken up by phagocytic cells. 
Radioactivity-based assessment of nanoparticle accumulation may not be proportional to 
cancer cell association.
The highly uniform size distribution of PRINT nanoparticles enabled examination of the 
influence of particle size. Reduction in particle size increased relative cancer cell 
association. Smaller sized particles have been shown to increase accumulation in 
tumors5,35,38 and may penetrate the extracellular matrix more efficiently enabling contact 
with a larger number of cancer cells. Alternatively, limitations based on the mechanism for 
cancer cell uptake may favor smaller particles. These data support our hypothesis that 
particle-specific features influence subtumoral distribution and that these features can be 
optimized to target specific cell populations in tumors and organs.
In conclusion, by quantifying nanoparticle uptake across the specific cellular compartments 
that constitute a tumor we have been able to explore the relative and absolute distribution of 
nanoparticles as well as identify the impact of altered particle properties. The analysis of 
nanoparticle accumulation on a cellular level provides important insights into the 
fundamental behavior of nanoparticles and the interplay between nanomedicines and the 
different physiological environment present within tumors and between tumors of different 
types. Cellular-level quantification is critical when assessing the function of impermeable 
cargo that depends on an intracellular mechanism of action.
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Figure 1. 
Particle accumulation measured by gamma radiation. (A) Radioactive emission was 
determined for each tissue 18 hours after intravenous administration. Fractional association 
for all tissues examined is shown. (B) Calculated mass of nanoparticles contained within 
tumor organ. Error bar indicates SD of n = 4.
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Figure 2. 
Flow cytometry gating strategy used to identify subtumoral compartments. To determine 
relative cell populations, dissociate tumor was stained with Fixable Blue, CD45, CD31, 
Ly6G and F4/80. Fluorescence minus one controls (grey lines) are used to distinguish 
significant staining (black). Representative plots are shown.
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Figure 3. 
Fractional composition of LKB498 xenografted tumors. Two groups of 16 animals were 
processed, with the data collected and analyzed separately then aggregated for the analysis. 
Error bars represent SD (n = 32).
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Figure 4. 
Nanoparticle association differs across cells comprising the tumor. Flow cytometric 
quantification of particle-positive cells. (A) LKB498 cancer cells, (B) Macrophages, (C) 
Neutrophils, (D) Other leukocytes (E) Endothelial cells, (F) Fibroblast/other cells. Error bar 
represents SD (n = 4 per dose group). * = p < 0.05 vs control, # = p < 0.05 vs 12.5 mg/kg.
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Figure 5. 
Mean fluorescence intensity of the particle-positive cells. Background fluorescence from the 
uninjected group was subtracted. Error bars represent SD (n = 4 per dose group).
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Figure 6. 
Nanoparticles preferentially concentrate in immune cells and decrease in tumor mass over 
time. (A) Two-photon images of tdTomato+ LKB498 melanoma spheroid tumor in murine 
ear dermis at 5 minutes before and 10 minutes, 24 hours, and 4 days after intravenous 
injection of Dylight488 conjugated nanoparticles. Maximum intensity projection, 
FV1000MPE, 14% power, 910 nm, 25× objective. Scale bar = 50 µm. (B) Two-photon 
images of tdTomato-positive cancer and infiltrating cells 24 hours postinjection of 
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Dylight488 conjugated nanoparticles. Maximum intensity projection; FV1000MPE, 14% 
power, 910 nm, 25× Objective, 3× Zoom. Scale bar = 50 µm.
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Figure 7. 
Nanoparticle size influences particle uptake in non-immune cells. Particle association for 
each cell type population was determined by flow cytometry. (A) LKB498 cancer cells, (B) 
Macrophages, (C) Neutrophils, (D) Other leukocytes (E) Endothelial cells, (F) Fibroblast/
other cells. Error bar represents SD (n = 6 per group). * = p<0.05 vs Sucrose, # = p<0.05 vs 
80×320.
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Figure 8. 
Mean fluorescence intensity was determined for particle-positive cells. Values were 
background corrected and error bars represent SD (n = 6 per dose group).
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